Integral Health Asset Management, LLC Uni Qure N.V. Transaction History

Integral Health Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$18.7 - $23.07 $935,000 - $1.15 Million	-50,000 Reduced 9.09%	500,000 $10.1 Million
Q4 2022 Feb 13, 2023	BUY	$18.12 - $27.32 $2.12 Million - $3.2 Million	117,000 Added 27.02%	550,000 $12.5 Million
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $1.36 Million - $2.04 Million	79,894 Added 22.63%	433,000 $8.12 Million
Q2 2022 Aug 03, 2022	BUY	$13.15 - $20.45 $2.41 Million - $3.74 Million	183,106 Added 107.71%	353,106 $6.58 Million
Q1 2022 May 12, 2022	BUY	$14.54 - $21.5 $1.02 Million - $1.51 Million	70,000 Added 70.0%	170,000 $3.07 Million
Q4 2021 Feb 02, 2022	BUY	$20.24 - $36.01 $2.02 Million - $3.6 Million	100,000 New	100,000 $2.07 Million
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $2.2 Million - $4.07 Million	-55,000 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$37.13 - $74.62 $2.04 Million - $4.1 Million	55,000 New	55,000 $3.94 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Integral Health Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Integral Health Asset Management, LLC with notifications on news.